Search
etesevimab
Indications:
- treatment of outpatients with COVID-19 >= 14 years of age >= 40 kg
- especially adults >= 65 years with COVID-19 at risk for severe disease
* must be administered in combination with bamlanivimab
Contraindications:
- not authorized in hospitalized patients or patients who require oxygen therapy for COVID-19
- bamlanivimab + etesevimab not effective against Omicron [3] (off market Jan 2022)
* may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation
Dosage:
- 2800 mg once by intravenous infusion
Mechanism of action:
- monoclonal antibody specifically directed against the spike protein of SARS-CoV2
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
monoclonal antibody to spike glycoprotein of SARS-CoV2 (COVID-19)
References
- Gottlieb RL, Nirula A, Chen P et al
Effect of Bamlanivimab as Monotherapy or in Combination With
Etesevimab on Viral Load in Patients With Mild to Moderate
COVID-19A Randomized Clinical Trial.
JAMA. Published online January 21, 2021
PMID: 33475701
https://jamanetwork.com/journals/jama/fullarticle/2775647
- Malani PN, Golub RM.
Neutralizing Monoclonal Antibody for Mild to Moderate COVID-19.
JAMA. Published online January 21, 2021
PMID: 33475716
https://jamanetwork.com/journals/jama/fullarticle/2775645
- Walker M
FDA OKs Antibody Combo for Milder COVID-19 -
Cut hospitalizations, deaths in patients at high risk of severe disease.
MedPage Today February 10, 2021
https://www.medpagetoday.com/infectiousdisease/covid19/91136
- American Medical Association (AMA)
AMA Morning Rounds. Jan 25, 2022